Russian drugmakers call for change in price calculations for state tenders

The Association of Pharmaceutical Manufacturers of the Eurasian Economic Union, a public association, which unites some leading Russian and global drugmakers operating in the former Soviet region, has called on the authorities of Russia to make adjustments for the methods of calculation of the initial maximum price of contracts (IMCP) for public procurements of drugs.

According to members of the Association, now the mechanism for determining the initial contract price does not take into account various factors, such as drug shortages, which leads to serious under-pricing during state actions and their failures, reports The Pharma Letter’s local correspondent.

As producers have said, public procurement tenders are often cancelled if the initial maximum contract price does not correspond to market realities. At the same time failed auctions lead to high costs of the state for the organization of new tenders and the overall therapy of patients in Russia.